Neurocrine Biosciences Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Neurocrine Biosciences Inc trades at $156 (market cap $16.46B), while Invesco WilderHill Clean Energy ETF trades at $34.63. Which is the better fit depends on your goals.
| NBIX | PBW | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $46.99 |
52-Week Low | $123.10 | $24.14 |
Enterprise Value | $16.48B | — |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
PBW (Invesco WilderHill Clean Energy ETF) trades at $34.87, up 0.75% today, with technical indicators showing a bullish trend supported by moving averages. The ETF benefits from growing clean energy demand driven by geopolitical tensions and data center energy needs. Recent news highlights PBW's 34% year-to-date gain despite volatility linked to interest rate cycles.
Outlook: Clean energy sector tailwinds from global investment and energy security concerns support growth, but sensitivity to Treasury yields and semiconductor market volatility poses risks. Investors should weigh sector momentum against macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →